Neogen Corporation (NEOG) Q1 FY2027 earnings

Reported results

• Revenue $222.8 million, growth 6.5% vs. prior-year quarter; Core revenue growth 8.1%
• Food Safety segment revenue $163.2 million, growth 7.4% with Core Growth of 8.1%
• Animal Safety segment revenue $59.6 million, growth 4.2% with Core Growth of 8.0%
• GAAP Net Loss $11.9 million, EPS $(0.05); Adjusted Net Income $17.5 million, Adjusted EPS $0.08
• Adjusted EBITDA $41.6 million with Adjusted EBITDA Margin 18.7%; cash from operations $12.9 million; free cash flow $4.7 million
• Gross Margin 47.4% GAAP; Adjusted Gross Margin 49.8%

Guidance

• FY2027 revenue guidance $885–$890 million (raised from $880–$885 million)
• FY2027 Adjusted EBITDA guidance $181–$183 million (raised from $180–$182 million)

Notes

Prior-year Q1 net income of $36.3 million included a non-cash gain of $76.4 million on the sale of the Cleaners & Disinfectants business. The company is on track to begin Petrifilm manufacturing transition in November 2026 and is pursuing the sale of its Genomics business to Zoetis, expected to close by end of December 2026.

Price and volatility reaction

The stock moved -2.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -18.1 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-06 (8-K, Item 2.02). Read the original filing on sec.gov.